News / Korea / yonhap_finance
Samsung Biologics Secures 350.8 Billion KRW CDMO Contract with European Pharma Firm
Health Technology · Biotechnology · yonhap_finance · 2026-09-10
207940
Samsung Biologics has signed a long-term CDMO contract worth approximately 350.8 billion KRW with a European pharmaceutical company, boosting its order backlog.
What Happened
Major Contract Win: Samsung Biologics has entered into a new CDMO agreement with a European pharmaceutical company valued at approximately 350.8 billion KRW. The contract is set to run through the end of 2033, providing a stable long-term revenue stream.
Cumulative Performance: With this latest deal, the company's cumulative order value since its inception has surpassed 21.9 billion USD (approx. 29.3 trillion KRW). This marks the sixth contract secured by the firm so far this year, underscoring its strong market position.
Strategic Significance: Securing such a large-scale, long-term contract amidst global economic uncertainty and intensifying competition in the CDMO sector is a significant achievement. The company continues to prioritize diversifying its client base and expanding production capacity.
Future Outlook: Samsung Biologics is actively expanding its business scope, including the acquisition of the PolyPeptide Group and the ongoing expansion of its Songdo production facilities. The firm remains focused on attracting new clients and deepening existing partnerships to meet global demand.